Literature DB >> 2886157

Neuroleptic malignant syndrome: review and analysis of 115 cases.

G Addonizio, V L Susman, S D Roth.   

Abstract

Neuroleptic malignant syndrome is a potentially fatal consequence of neuroleptic use that has recently gained wide attention. In this article the authors critically review the previous literature and analyze all case reports in the English-language literature (115 cases) for 43 variables. The results are discussed in light of prior literature, and recommendations are made for future research.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2886157     DOI: 10.1016/0006-3223(87)90010-2

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  42 in total

1.  Neuroleptic malignant syndrome in a patient with citrullinaemia.

Authors:  A Dursun; Y Yilma; M Ozsari; N Kandemir; T Coşkun
Journal:  J Inherit Metab Dis       Date:  2000-12       Impact factor: 4.982

2.  Neuroleptic malignant syndrome: evaluation of drug safety data from the AMSP program during 1993-2015.

Authors:  Michael Schneider; Johannes Regente; Timo Greiner; Stephanie Lensky; Stefan Bleich; Sermin Toto; Renate Grohmann; Susanne Stübner; Martin Heinze
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-11-30       Impact factor: 5.270

Review 3.  Diagnosis and management of acute movement disorders.

Authors:  D Dressler; R Benecke
Journal:  J Neurol       Date:  2005-10-10       Impact factor: 4.849

4.  Case files of the program in medical toxicology at brown university: amantadine withdrawal and the neuroleptic malignant syndrome.

Authors:  Eric Brantley; Jamieson Cohn; Kavita Babu
Journal:  J Med Toxicol       Date:  2009-06

5.  Neuropharmacology of dopamine receptors:: Implications in neuropsychiatric diseases.

Authors:  F I Tarazi
Journal:  J Sci Res Med Sci       Date:  2001-10

Review 6.  Use of phenothiazines as sedatives in children: what are the risks?

Authors:  K S Dyer; A D Woolf
Journal:  Drug Saf       Date:  1999-08       Impact factor: 5.606

7.  Muscle changes in the neuroleptic malignant syndrome.

Authors:  W M Behan; M Madigan; B J Clark; J Goldberg; D R McLellan
Journal:  J Clin Pathol       Date:  2000-03       Impact factor: 3.411

8.  Cerebellar gait ataxia following neuroleptic malignant syndrome.

Authors:  M Manto; S Goldman; J Hildebrand
Journal:  J Neurol       Date:  1996-01       Impact factor: 4.849

9.  Amantadine and the glutamate hypothesis of schizophrenia. Experiences in the treatment of neuroleptic malignant syndrome.

Authors:  J Kornhuber; M Weller
Journal:  J Neural Transm Gen Sect       Date:  1993

10.  Prevalence of neuroleptic malignant syndrome in 672 consecutive male in-patients.

Authors:  Pradyot Sarkar; Chandrashekhar Natarajan; Neeta Gode
Journal:  Indian J Psychiatry       Date:  2009 Jul-Sep       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.